We report a case series of dopamine dysregulation syndrome, previously known as hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies, now designated as Lees' syndrome.
Parkinson's disease (PD) is a neurodegenerative, progressive disorder, affecting several monoaminergic systems (dopamine, noradrenaline, acetylcholine, serotonin) of the central nervous system 1 . Classically, PD presents with well defined motor signs: bradykinesia, rigidity, rest tremor, and postural instability. Additionally, non-motor symptoms and signs are present in most, if not all cases, including neuro-psychiatric (e.g., depression, anhedonia, anxiety), sleep disorders (e.g., REM sleep behavior disorder, sleep fragmentation), dysautonomia (e.g., orthostatic hypotension, urinary incontinence), gastrointestinal (e.g., constipation, dysphagia), sensory (e.g., pain, hyposmia), as well as other less common symptoms (e.g., fatigue, weight loss, seborrhea) [1] [2] [3] . Currently, motor symptoms and signs in PD, most of them dopaminergic, can be managed with therapeutic options that include monoamine oxidase type B inhibitors (rasagiline and selegeline), dopamine agonists (e.g., pramipexole, ropinirole, piribedil, rotigotine), levodopa, catechol-O-methyl transferase inhibitors (entacapone and tolcapone), and amantadine 1,2 . However, several complications may occur in PD patients using levodopa, after a mean of three to five years, the so-called "honeymoon period". These complications occur commonly in the form of motor fluctuations and dyskinesias 2 . Later in the disease course, dopamine replacement therapy may also induce non-motor complications that include behavioral disturbances such as hypersexuality, impulse control disorders (e.g., pathological gambling, shopping, eating), aggression, hypomania, punding, craving and psychosis 1 . Among these later complications of dopaminergic treatment, is the dopamine dysregulation syndrome (DDS), previously defined as homeostatic hedonistic syndrome, currently also designated as Lees' syndrome (LS) 4 . The objective of this study is to present a series of LS in patients with PD. Lees' syndrome Becker et al.
CASES
We selected eight patients with PD, followed at the Movement Disorders Service of the Federal University of Paraná and at the Paraná Parkinson Association, who fulfilled criteria for the diagnosis of LS 5 . Diagnosis of PD was based on the Queen Square Brain Bank criteria 6 .
Illustrative case
A 57 year-old man, with an established diagnosis of early onset PD at the age of 43 years, started, after five years of treatment with levodopa, with motor fluctuations (wearing-off and on-off phenomena), severe peak dose dyskinesias, disabling dysarthria, hypophonia, as well as treatment refractory gait disturbances. After 10 years from diagnosis the patient underwent a right stereotactic thalamotomy performed at another service, with relative improvement on contralateral resting tremor. After another two years, He started to present re emergence of right upper limb tremor and progressive worsening of dyskinesias, also more prominent on the right. At this time he started using up to 12 tablets of levodopa/carbidopa 250/25 mg per day, compulsively and, at times, unnecessarily, according to his wife's judgment. His drug regimen also included amantadine 100 mg bid, amitriptyline 25 mg 2 tablet bd for depressive symptoms and clonazepam 2 mg at bed time. Previously he temporarily used biperiden and pramipexole, both withdrawn due to side effects. His wife also reported episodes in which he left the house after taking two to three extra levodopa/carbidopa tablets, driving erratically at high speeds, seeking for medication obsessively at pharmacies, even after receiving medical advice to reduce its intake in several occasions. Additionally, he reported intense anxiety during medication cravings, including psychomotor agitation, restlessness, aggression towards relatives, diaphoresis, and multiple behavioral changes, including hypersexuality that led his wife to sleep in a separate room with his teenage daughter, fearing possible abuse. The patient had no co-morbidities, but his past medical history was positive for tobacco use and alcoholism. He denied illicit drug use.
General examination was unremarkable. Mini mental score examination was 20. There were dysarthria and hypophonia. Motor examination in the ON medication state showed mild rigidity on the right limbs with severe dyskinesias that spread to the neck and face.
He was admitted to the hospital, and after levodopa dosage reduction, dyskinesias improved dramatically, however, this was accompanied by significant worsening of rigidity and bradykinesia, depressive symptoms, anxiety, and continuous demand for levodopa. The later was re introduced at the dose of one tablet qid, along with Table. DISCUSSION The DDS in patients with PD was described initially in 2000, by Giovannoni et al., using the term hedonistic homeostatic dysregulation 5 . This designation was originally created in 1997, by Koob and Le Moal, to define the drug abuse syndrome, characterized by the compulsive and uncontrolled use of drugs, due to dysfunction of cerebral reward systems, including the dopaminergic mesocorticolymbic pathway 7 . Drug addiction to drugs such as amphetamine and cocaine, is a chronic, relapsing disorder, characterized basically by compulsive demand for the specific substances, with loss of control over the necessity to limit its use, and with the occurrence of negative emotional states (anxiety, irritability and dysphoria), similar to the picture of abstinence when a drug is abruptly withdrawn 7, 8 . From an anatomophysiological standpoint, the neuro-circuitry related to drug addiction involves particularly the ventral striatum, with crucial participation of the nucleus accumbens 8 . From a historical perspective, there are several case reports, starting in 1971, describing excessive intake of levodopa accompanied by behavioral disturbances, as well as what is described as levodopa addiction, in patients with PD [9] [10] [11] [12] [13] [14] [15] . The case report by Nausieda, for instance, describes what he referred to as "Sinemet abusers", in 1985 12 . Literature review shows a total of 63 publications on DDS between 2000 and 2010. The 10 most relevant, with well defined prevalence rates, diagnostic criteria, speculations on physiopathogenic hypothesis, and analysis of comorbidities were all published by Professor Andrew Lees' research group from London, UK. Accordingly, as suggested by Evans and Giovannoni in 2008, DDS can adequately be designated as LS 4 . LS is a rare iatrogenic complication, observed among PD patients with a history of long term use of dopamine replacement therapy, characterized by the excessive use of dopaminomimetic agents, beyond what is necessary for adequate motor symptom control. Dopaminergic drug abuse, is associated with the development of severe dyskinesias and multiple behavioral disturbances, including restlessness, psychomotor overactivity, aggression, hypomania, dysphoria, anhedonia, and irritability during OFF medication periods, with compulsive demand for dopaminergic drugs 6, [16] [17] [18] [19] . Another behavioral disturbance found in these patients is punding, defined as a complex stereotyped behavior, characterized by severe fascination for repetitive manipulation of technical equipments, by the act of collecting, examining and handling common objects, as well as driving vehicles purposeless or wandering [16] [17] [18] 20 . Also, Bonvin et al. recently proposed that compulsive singing can be a another form of punding in PD 21 . Additionally, other behavioral disturbances found in LS include craving and psychosis [16] [17] [18] . LS may also encompass impulse control disorders such as hypersexuality, pathological gambling, compulsive shopping and compulsive eating 6, [16] [17] [18] [22] [23] [24] . The prevalence of LS is estimated to range from 3.4% 25 to 4.1% 6 , with the caveat that these numbers were gathered from highly specialized tertiary centers. In Brazil, references are limited to a study that assessed 100 patients with PD, where no case of LS was detected 26 , and a single case report by Kummer et al. 27 . The illustrative case presented here, in a 58 year old male with a 14 year history of early onset PD, we can detect the typical excessive and compulsive use of levodopa, beyond what is necessary to control motor symptoms of PD, with the occurrence of severe dysphoria, irritability, and anxiety during OFF medication periods, associated with drenching sweats and excessive seeking and demand for levodopa. This case also had a previous history of alcoholism and tobacco use, with signs of depression as well as hypersexuality. Another interesting aspect described here is the "self prescribed" increase in levodopa dose, with dangerous impulsive driving, already described by Avanzi et al. 28 . Among the remaining cases described here, we also confirmed a significant predominance of male patients, with hypersexuality, and alcohol abuse.
Among the risk factors for the development of LS are PD onset at an early age, impulsive and sensationseeking personality traits, history of alcohol and drug abuse, previous depression, as well as impulse control disorders, punding, sleep disturbances, among others 17, 29 . Schwingenschuh et al., questioned in a recent publication if PD patients engaged in artistic professional activities are at potential risk for LS 30 . The physiopathogenic mechanisms for LS are not yet fully understood and described, however, the theory developed by Robinson and Berridge has been speculated. These authors created the incentive sensitization theory to explain LS 6, [16] [17] [18] 31 , defining that compulsive drug use occurs due to progressive neuro-adaptations formed along dopaminergic projections linked to the ventral striatum, particularly the nucleus accumbens 31 . This implies in persistent abnormalities in dopaminergic and GABAergic transmission, with the development of sensitization and activation of reward pathways linked to the nucleus accumbens, defined as incentive salience 31 . Recent functional neuroimaging studies, such as the one published by Evans et al. in 2006 , confirmed that compulsive drug use is linked to the development of sensitization of ventral striatal dopaminergic transmission 32 . This sensitization induced by the use of levodopa in patients with PD, correlates with compulsive-drug seeking and punding behavior 32 . Treatment of LS has been extensively discussed. O'Sullivan et al. proposed treatment with psychotherapic interventions, including cognitive-behavioral therapy, surgical interventions in well selected cases (STN DBS), and pharmacological treatment with withdrawal of short acting levodopa formulations and subcutaneous apomorphine 6 . For the management of impulse control disorders, withdrawal of dopamine agonists has been suggested; for the treatment of hypomania and psychosis, the use of quetiapine, clozapine or even aripiprazole. Citalopram is the drug of choice for the treatment of depression, particularly if compulsive shopping is present. For the treatment of pathological gambling, opioid antagonists, lithium, valproate or carbamazepine. Amantadine has been used for the management of punding, dyskinesias and pathological gambling 6, 33 .
